2.7.7.18	analysis	NMNAT can be applied to the colorimetric NMN or NaMN assays, which employ either adenylation of NMN to NAD by NMNAT or adenylation of NaMN to deamido-NAD (NaAD) by NMNAT followed by amidation of NaAD to NAD by NAD synthetase (NADS, EC 6.3.1.5) or an NAD cycling reaction using 12alpha-hydroxysteroid dehydrogenase (12a-HSD, EC 1.1.1.176) and diaphorase (DI, EC 1.6.99.3) to accumulate reduced 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium. The enzymatic cycling method enables detection of 0.5 mM (12.2 nM in the reaction mixture) NMN or NaMN in an automatic clinical analyzer	761553	
2.7.7.18	drug development	enzyme NadD is a potentially druggable target suitable for the development of selective inhibitors	-, 738672	
2.7.7.18	drug development	the enzyme is a target for inhibitor development	695360	
2.7.7.18	medicine	loss of function mutations in two stillborn siblings lead to fetal akinesia deformation sequence, severely reduced skeletal muscle mass and hydrops fetalis. Both protein variants are incapable of supporting axon survival in mouse primary neuron cultures when overexpressed. Variants display altered protein stability and/or defects in NAD+ synthesis and chaperone functions	761048	
2.7.7.18	medicine	the enzyme is a target for developing antimycobacterial therapies	-, 738672	
2.7.7.18	synthesis	overexpression of enzyme gene under anaerobic conditions in a strain lacking IdhA and pflB gene products leads to 3.21fold increase in NAD+ and 1.67fold increase in NADH in the recombinant strain. Enzyme expression restores cell growth and glucose utilization under anaerobic conditions. After 72 h, the recombinant strain can consume 14 g/l of lgucose and produce 6.23 g/l of succinic acid	722069